» Articles » PMID: 38702326

LncRNA IL21-AS1 Facilitates Tumour Progression by Enhancing CD24-induced Phagocytosis Inhibition and Tumorigenesis in Ovarian Cancer

Overview
Journal Cell Death Dis
Date 2024 May 3
PMID 38702326
Authors
Affiliations
Soon will be listed here.
Abstract

CD24 is overexpressed in various tumours and considered a regulator of cell migration, invasion, and proliferation. Recent studies have found that CD24 on ovarian cancer (OC) and triple-negative breast cancer cells interacts with the inhibitory receptor sialic-acid-binding Ig-like lectin 10 (Siglec-10) on tumour-associated macrophages (TAMs) to inhibit phagocytosis by macrophages. Because of its multiple roles in regulating the immune response and tumorigenesis, CD24 is a very promising therapeutic target. However, the regulatory mechanism of CD24 in OC remains unclear. Here, we found that the long noncoding RNA (lncRNA) IL21-AS1, which was upregulated in OC, inhibited macrophage-mediated phagocytosis and promoted OC cell proliferation and apoptosis inhibition. More importantly, after IL21-AS1 knockdown, a significant survival advantage was observed in mice engrafted with tumours. Mechanistically, we identified IL21-AS1 as a hypoxia-induced lncRNA. Moreover, IL21-AS1 increased HIF1α-induced CD24 expression under hypoxic conditions. In parallel, we found that IL21-AS1 acted as a competing endogenous RNA (ceRNA) for miR-561-5p to regulate CD24 expression. Finally, IL21-AS1 increased CD24 expression in OC and facilitated OC progression. Our findings provide a molecular basis for the regulation of CD24, thus highlighting a potential strategy for targeted treatment of OC.

Citing Articles

Competing endogenous RNA networks in ovarian cancer: from bench to bedside.

Derogar R, Nejadi Orang F, Shadbad M EXCLI J. 2025; 24:86-112.

PMID: 39967908 PMC: 11830916. DOI: 10.17179/excli2024-7827.


Long Non-Coding RNAs in Ovarian Cancer: Mechanistic Insights and Clinical Applications.

Basu S, Nadhan R, Dhanasekaran D Cancers (Basel). 2025; 17(3).

PMID: 39941838 PMC: 11815776. DOI: 10.3390/cancers17030472.


The ncRNA-AURKA Interaction in Hepatocellular Carcinoma: Insights into Oncogenic Pathways, Therapeutic Opportunities, and Future Challenges.

Garcia C, Grisetti L, Tiribelli C, Pascut D Life (Basel). 2024; 14(11).

PMID: 39598228 PMC: 11595987. DOI: 10.3390/life14111430.

References
1.
Su D, Deng H, Zhao X, Zhang X, Chen L, Chen X . Targeting CD24 for treatment of ovarian cancer by short hairpin RNA. Cytotherapy. 2009; 11(5):642-52. DOI: 10.1080/14653240902878308. View

2.
Poliseno L, Salmena L, Zhang J, Carver B, Haveman W, Pandolfi P . A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010; 465(7301):1033-8. PMC: 3206313. DOI: 10.1038/nature09144. View

3.
Benskey M, Manfredsson F . Lentivirus Production and Purification. Methods Mol Biol. 2015; 1382:107-14. DOI: 10.1007/978-1-4939-3271-9_8. View

4.
Feng M, Jiang W, Kim B, Zhang C, Fu Y, Weissman I . Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer. 2019; 19(10):568-586. PMC: 7002027. DOI: 10.1038/s41568-019-0183-z. View

5.
Panagiotou E, Syrigos N, Charpidou A, Kotteas E, Vathiotis I . CD24: A Novel Target for Cancer Immunotherapy. J Pers Med. 2022; 12(8). PMC: 9409925. DOI: 10.3390/jpm12081235. View